Freixa, Xavier; Llull, Laura; Gafoor, Sameer; Cruz-Gonzalez, Ignacio; Shakir, Samera; Omran, Heyder; Berti, Sergio; Santoro, Gennaro; Kefer, Joelle; Landmesser, Ulf; Nielsen-Kudsk, Jens Erik; Kanagaratnam, Prapa; Nietlispach, Fabian; Glökler, Steffen; Aminian, Adel; Danna, Paolo; Rezzaghi, Marco; Stock, Friederike; Stolcova, Miroslava; Paiva, Luis; ... (2016). Characterization of Cerebrovascular Events After Left Atrial Appendage Occlusion. American journal of cardiology, 118(12), pp. 1836-1841. Elsevier 10.1016/j.amjcard.2016.08.075
Text
1-s2.0-S0002914916314916-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (225kB) |
Cardioembolic strokes are generally more lethal and disabling than other source of strokes. Data from PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) suggest that strokes after left atrial appendage occlusion (LAAO) with the Watchman device are less disabling than those in the warfarin group. No data assessing the severity of strokes after LAAO with the AMPLATZER Cardiac Plug (ACP) are available. The objective of the study was to evaluate the severity of cerebrovascular events after LAAO with the ACP in a population mostly characterized by an absolute or relative contraindication to oral anticoagulation. Data from the ACP multicenter registry were analyzed. Disabling strokes were defined as those with a modified Rankin score of 3 to 6 at 90 days after the event. A total of 1,047 subjects were included. The mean age and CHADS2 score were 75 ± 8 years and 2.8 ± 1.3, respectively. Procedural success was achieved in 97.3% and 4.9% of the patients presented procedural major adverse events. Clinical follow-up was complete in 98.2% of patients with a median of 13 months. There were 9 strokes (0.9%), 9 transient ischemic attacks (0.9%), and no intracranial hemorrhages (0%) at follow-up. After excluding 2 patients with pre-LAAO disability, functional assessment showed disabling events in 3 (19%) of the remaining 16 patients. The median time of presentation was 420 days (interquartile range 234 to 671) after LAAO, and 17 patients (94%) were on single-antiplatelet therapy when the event occurred. According to our results, cerebrovascular events after LAAO with the ACP system were infrequent and mostly nondisabling.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology |
UniBE Contributor: |
Shakir, Samera, Glökler, Steffen, Meier, Bernhard |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0002-9149 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Daria Vogelsang |
Date Deposited: |
22 Mar 2017 08:17 |
Last Modified: |
05 Dec 2022 15:01 |
Publisher DOI: |
10.1016/j.amjcard.2016.08.075 |
PubMed ID: |
27745964 |
BORIS DOI: |
10.7892/boris.92567 |
URI: |
https://boris.unibe.ch/id/eprint/92567 |